Your Momma's Degrassi Blog @sassidegrassi - Tumblr Blog

twuwfm

winchysteria

the only true ally

thememedaddy

aromanticduck

If neurotypicals are so good at picking up hints, why do they never seem to notice you leaning away when they try to touch you?

tallysgreatestfan

If neurotypicals are so empathic and social, why do they not notice when they are mean as fuck?

aromanticduck

If neurotypicals are so adaptable to change, why won’t they make accommodations for neurodivergent people?

latex-salesman

pressworksonpaperblog

from “the popeye and friends knitting book”, 1989.

lockpendant

Aya Takano / Summoning her owls, she looked yonder. The buildings shone. (details) / 2007

theswampghost

“my child is fine” your child has the 1985 film Clue memorized

cornedbeefhashtags

chloesevignygf

hysteric glamour reversible patchwork bag

sanctus

victorian scottish agate and gold locket bracelet

zegalba

saxifraga-x-urbium

Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form

fucking livid

partisan-by-default

Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form sticky plaques in the brains of Alzheimer’s disease patients. The drug had been particularly effective in animal models, and the trial results were eagerly awaited as one of the most promising treatments in years. It did not work. “Crenezumab did not slow or prevent cognitive decline” in people with a predisposition toward Alzheimer’s.

Last year, the Food and Drug Administration (FDA) narrowly approved the use of Aduhelm, a new drug from Biogen that the company has priced so highly that it’s expected to drive up the price of Medicare for everyone in America, even those who never need this drug. Aduhelm was the first drug to be approved that fights the accumulation of those "amyloid plaques" in the brain. What makes the approval of the $56,000-a-dose drug so controversial is that while it does decrease plaques, it doesn’t actually slow Alzheimer’s. In fact, clinical trials were suspended in 2019 after the treatment showed “no clinical benefits.” (Which did not keep Biogen from seeking the drug’s approval or pricing it astronomically.)

Over the last two decades, Alzheimer’s drugs have been notable mostly for having a 99% failure rate in human trials. It’s not unusual for drugs that are effective in vitro and in animal models to turn out to be less than successful when used in humans, but Alzheimer’s has a record that makes the batting average in other areas look like Hall of Fame material.

And now we have a good idea of why. Because it looks like the original paper that established the amyloid plaque model as the foundation of Alzheimer’s research over the last 16 years might not just be wrong, but a deliberate fraud.

saxifraga-x-urbium

thanks for the text extraction, i was on my phone <3

weird-ecologies

Jesus christ

shofarsogood

Image description of the previous box: an excerpt from the article that reads,

In the face of potential fraud unearthed by Schrag, it's not as of the world has changed overnight.

Four months after Schrag submitted his concerned to the NIH, the NIH turned around and awarded Lesné a five-year grant to study... Alzheimer's. The grants was awarded by Austin Yang, program director at the NIH's National Institute on Aging. Yang also happens to be another of the co-authors on the 2006 paper.

"A five year grant" and "Austin Yang" are orange hyperlinks. End description.